Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pixu 2 decoction is a traditional Chinese medicine (TCM) herbal formula developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment of functional dyspepsia (FD) characterized by "Pixu" (spleen deficiency) patterns. In TCM theory, the spleen is central to digestion, and its deficiency leads to symptoms like bloating, early satiety, and epigastric pain. Pixu 2 is one of three experimental decoctions (alongside Pixu 1 and Pixu 3) used in differential diagnosis-based treatment protocols. It was evaluated in a multicenter, randomized, double-blind, placebo-controlled clinical trial in China to assess its efficacy and safety in relieving dyspeptic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pixu 2 decoction.